Glycemic and Economic Outcomes in Elderly Patients with Type 2 Diabetes Initiating Dulaglutide Versus Basal Insulin in a Real-World Setting in the United States: The DISPEL-Advance Study

[1] Abd El Aziz MS(2018)Economic costs of diabetes in the U.S. in 2017 Diabetes Care 41 917-928

[2] Kahle M(2017)A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients Diabetes Obes Metab 19 216-227

[3] Meier JJ(2019)Clinical and economic outcomes among injection-naïve patients with type 2 diabetes initiating dulaglutide compared with basal insulin in a US real-world setting: the DISPEL study BMJ Open Diabetes Res Care 7 S216-S229

[4] Nauck MA(2022)13. Older adults: standards of care in diabetes—2023 Diabetes Care 46 156-167

[5] Mody R(2015)Hypoglycemia in older people—a less well recognized risk factor for frailty Aging Dis 6 1190-1194

[6] Huang Q(2018)Use of intensive glycemic management in older adults with diabetes mellitus J Am Geriatr Soc 66 2570-2576

[7] Yu M(2022)Medical costs associated with diabetes complications in Medicare beneficiaries aged 65 years or older with type 2 diabetes Diabetes Care 45 126-133

[8] ElSayed NA(2012)Association of patient-centered outcomes with patient-reported and ICD-9-based morbidity measures Ann Fam Med 10 676-682

[9] Aleppo G(2011)Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries Am J Epidemiol 173 721-726

[10] Aroda VR(2012)Validating the adapted Diabetes Complications Severity Index in claims data Am J Manag Care 18 1007-1013

[1] Abd El Aziz MS(2018)Economic costs of diabetes in the U.S. in 2017 Diabetes Care 41 917-928

[2] Kahle M(2017)A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients Diabetes Obes Metab 19 216-227

[3] Meier JJ(2019)Clinical and economic outcomes among injection-naïve patients with type 2 diabetes initiating dulaglutide compared with basal insulin in a US real-world setting: the DISPEL study BMJ Open Diabetes Res Care 7 S216-S229

[4] Nauck MA(2022)13. Older adults: standards of care in diabetes—2023 Diabetes Care 46 156-167

[5] Mody R(2015)Hypoglycemia in older people—a less well recognized risk factor for frailty Aging Dis 6 1190-1194

[6] Huang Q(2018)Use of intensive glycemic management in older adults with diabetes mellitus J Am Geriatr Soc 66 2570-2576

[7] Yu M(2022)Medical costs associated with diabetes complications in Medicare beneficiaries aged 65 years or older with type 2 diabetes Diabetes Care 45 126-133

[8] ElSayed NA(2012)Association of patient-centered outcomes with patient-reported and ICD-9-based morbidity measures Ann Fam Med 10 676-682

[9] Aleppo G(2011)Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries Am J Epidemiol 173 721-726

[10] Aroda VR(2012)Validating the adapted Diabetes Complications Severity Index in claims data Am J Manag Care 18 1007-1013